Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B ROTHMAN

Showing results (451-460 of 606) with videos related to

Pageof 61
Sort By:
Synapse (New York, N.Y.)|November 9, 2000
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assayH Xu, A Hashimoto, K C Rice, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2006
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ringWayne W Harding, Matthew Schmidt, Kevin Tidgewell, et al.
Synapse (New York, N.Y.)|December 8, 2006
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependenceHeng Xu, John S Partilla, Xiaoying Wang, et al.
Journal of Medicinal Chemistry|July 22, 2005
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligandsWayne W Harding, Kevin Tidgewell, Nathan Byrd, et al.
European Journal of Pharmacology|August 29, 1989
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypesR B Rothman, C P France, V Bykov, et al.
NIDA Research Monograph|January 1, 1989
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of actionL Band, V Bykov, N Greig, et al.
Synapse (New York, N.Y.)|September 29, 1999
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assayD V Romero, J S Partilla, Q X Zheng, et al.
Peptides|January 8, 1999
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptidesC B Goodman, S Heyliger, B Emilien, et al.
Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.
NIDA Research Monograph|January 1, 1991
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamineR B Rothman, A Mele, A A Reid, et al.
Pageof 61

Showing results (451-460 of 606) with videos related to

Sort By:
Pageof 61
Synapse (New York, N.Y.)|November 9, 2000
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assayH Xu, A Hashimoto, K C Rice, et al.
Bioorganic & Medicinal Chemistry Letters|April 20, 2006
Synthetic studies of neoclerodane diterpenes from Salvia divinorum: selective modification of the furan ringWayne W Harding, Matthew Schmidt, Kevin Tidgewell, et al.
Synapse (New York, N.Y.)|December 8, 2006
A comparison of noninternalizing (herkinorin) and internalizing (DAMGO) mu-opioid agonists on cellular markers related to opioid tolerance and dependenceHeng Xu, John S Partilla, Xiaoying Wang, et al.
Journal of Medicinal Chemistry|July 22, 2005
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligandsWayne W Harding, Kevin Tidgewell, Nathan Byrd, et al.
European Journal of Pharmacology|August 29, 1989
Pharmacological activities of optically pure enantiomers of the kappa opioid agonist, U50,488, and its cis diastereomer: evidence for three kappa receptor subtypesR B Rothman, C P France, V Bykov, et al.
NIDA Research Monograph|January 1, 1989
In vivo binding of (+)-cis methylfentanyl at the opiate receptor complex and behavioral correlates: evidence for a novel mechanism of actionL Band, V Bykov, N Greig, et al.
Synapse (New York, N.Y.)|September 29, 1999
Opioid peptide receptor studies. 12. Buprenorphine is a potent and selective mu/kappa antagonist in the [35S]-GTP-gamma-S functional binding assayD V Romero, J S Partilla, Q X Zheng, et al.
Peptides|January 8, 1999
Regulation of mu binding sites after chronic administration of antibodies directed against specific anti-opiate peptidesC B Goodman, S Heyliger, B Emilien, et al.
Psychopharmacology|September 1, 1996
Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaineJ K Staley, Q Ouyang, J Pablo, et al.
NIDA Research Monograph|January 1, 1991
Preliminary evidence that the high affinity dopamine reuptake inhibitor, GBR12909, antagonizes the ability of cocaine to elevate extracellular levels of dopamineR B Rothman, A Mele, A A Reid, et al.
Pageof 61